Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ocular Therapeutix stock | 13.78

Own Ocular Therapeutix stock in just a few minutes.

Posted

Fact checked

Ocular Therapeutix, Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 161 staff and has a trailing 12-month revenue of around USD$12.3 million.

How to buy shares in Ocular Therapeutix

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ocular Therapeutix. Find the stock by name or ticker symbol: OCUL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocular Therapeutix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ocular Therapeutix, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ocular Therapeutix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Ocular Therapeutix's share price?

Since the stock market crash in March caused by coronavirus, Ocular Therapeutix's share price has had significant positive movement.

Its last market close was USD$13.78, which is 59.00% up on its pre-crash value of USD$5.65 and 265.03% up on the lowest point reached during the March crash when the shares fell as low as USD$3.775.

If you had bought USD$1,000 worth of Ocular Therapeutix shares at the start of February 2020, those shares would have been worth USD$1,066.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,048.69.

Ocular Therapeutix share price

Use our graph to track the performance of OCUL stocks over time.

Ocular Therapeutix shares at a glance

Information last updated 2020-11-19.
Latest market close USD$13.78
52-week range USD$2.92 - USD$14.16
50-day moving average USD$10.9168
200-day moving average USD$8.6974
Wall St. target price USD$14.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.79

Buy Ocular Therapeutix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ocular Therapeutix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocular Therapeutix price performance over time

Historical closes compared with the close of $13.78 from 2020-11-16

1 week (2020-11-16) 13.78
1 month (2020-10-26) 41.62%
3 months (2020-08-24) 70.97%
6 months (2020-05-22) 90.86%
1 year (2019-11-22) 334.70%
2 years (2018-11-23) 142.61%
3 years (2017-11-24) 232.05%
5 years (2015-11-24) 57.67%

Ocular Therapeutix financials

Revenue TTM USD$12.3 million
Gross profit TTM USD$-39,189,000
Return on assets TTM -46.75%
Return on equity TTM -2677.1%
Profit margin 0%
Book value $0.085
Market capitalisation USD$964.5 million

TTM: trailing 12 months

Shorting Ocular Therapeutix shares

There are currently 6.2 million Ocular Therapeutix shares held short by investors – that's known as Ocular Therapeutix's "short interest". This figure is 11.2% down from 6.9 million last month.

There are a few different ways that this level of interest in shorting Ocular Therapeutix shares can be evaluated.

Ocular Therapeutix's "short interest ratio" (SIR)

Ocular Therapeutix's "short interest ratio" (SIR) is the quantity of Ocular Therapeutix shares currently shorted divided by the average quantity of Ocular Therapeutix shares traded daily (recently around 1.6 million). Ocular Therapeutix's SIR currently stands at 3.77. In other words for every 100,000 Ocular Therapeutix shares traded daily on the market, roughly 3770 shares are currently held short.

However Ocular Therapeutix's short interest can also be evaluated against the total number of Ocular Therapeutix shares, or, against the total number of tradable Ocular Therapeutix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocular Therapeutix's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Ocular Therapeutix shares in existence, roughly 90 shares are currently held short) or 0.0969% of the tradable shares (for every 100,000 tradable Ocular Therapeutix shares, roughly 97 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocular Therapeutix.

Find out more about how you can short Ocular Therapeutix stock.

Ocular Therapeutix share dividends

We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.

Ocular Therapeutix share price volatility

Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $2.92 up to $14.16. A popular way to gauge a stock's volatility is its "beta".

OCUL.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 1.6979. This would suggest that Ocular Therapeutix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ocular Therapeutix overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site